SCHEMBL20249148

SCHEMBL20249148

CC(C)(C)c1ccc(CN2CCNCC2=O)cn1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 1/20 0.40
CDK6 Q00534 1/20 0.40
CCR9 P51686 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GPR4 P46093 1/20 0.35
KCNH2 Q12809 1/20 0.35
CHRNA1 P02708 2/20 0.34
CHRNA7 P36544 2/20 0.34
CHRNA3 P32297 1/20 0.34
TRPC5 Q9UL62 1/20 0.34
PPARD Q03181 1/20 0.34
CXCR4 P61073 2/20 0.33
TP53 P04637 1/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18291305 0.82 CHRM1 (0.44) CDK4CDK6SMN1; SMN2GPR4KCNH2
SCHEMBL20249153 0.82 ALDH1A1 (0.51) CCR9SMN1; SMN2ALDH1A1CHRNA1CHRNA7
SCHEMBL20249210 0.81 L3MBTL1 (0.49) CCR9KCNH2
SCHEMBL20038452 0.80 CDK4 (0.41) CDK4CDK6SMN1; SMN2ALDH1A1GPR4
SCHEMBL18291271 0.80 CDK4 (0.41) CDK4CDK6SMN1; SMN2ALDH1A1GPR4
SCHEMBL20249280 0.79 NPC1 (0.38) SMN1; SMN2ALDH1A1
SCHEMBL20224126 0.79 CXCR4 (0.49) PPARDCXCR4
SCHEMBL20249150 0.79 SMN1; SMN2 (0.62) CCR9SMN1; SMN2ALDH1A1CHRNA1CHRNA7
SCHEMBL20037443 0.79 CDK4 (0.50) CDK4CDK6SMN1; SMN2ALDH1A1GPR4
SCHEMBL20249207 0.78 CYP11B2 (0.40) CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 CDK4 1/4885CDK6 2/4885CCR9 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.